Hybrid care nutrition and mental wellness program delivery

Summary

This research aims to see how the LyfeMD app affects patients and their use of healthcare services. The program in LyfeMD app combines a health professional (Health Coach + Registered Dietician) and a digital care program, which offers various educational programs to improve nutrition, sleep, stress, depression, anxiety, physical activity, and cognitive behaviour.

The study will compare 45 high-risk patients with health issues such as malnutrition, ongoing diseases, opioid use, and mental health problems. These patients will receive the LyfeMD app, virtual health coaching, and support from a registered dietitian. The study will also compare the healthcare usage of these patients before and after using the LyfeMD program with their own healthcare data from the year before.

Eligibility

Currently recruiting participants: No

Eligible ages: 18 to 75

Inclusion criteria:

1) ≥ 18 to ≤ 75 years of age; and
2) one of the e following
(i) malnutrition risk, assessed by the gastroenterologist; OR
(ii) mild-to-moderate depression, defined as a PHQ-9 score ≥ 5 to < 15; OR
(iii) mild-to-moderate anxiety, defined as a Generalized Anxiety Disorder 7-item (GAD-7) score ≥ 5 to < 15;45 OR
(iv) food security issues, OR
(v) regular use of opioids used for chronic pain management; OR
(vi) mild to moderately active Crohn's disease measured by a Harvey Bradshaw index ≥5 and ≤16 or Ulcerative colitis measured by total, partial Mayo score ≥ 2 and ≤6.

Exclusion criteria:

1) severe depression (PHQ-9 ≥ 15) or anxiety (GAD-7 ≥ 15) (if patients meeting these criteria are identified, they will be referred to the clinic counsellor for assessment;
2) non-English speaking;
4) presence of fistulizing disease; or
5) other major health issues: chronic kidney disease, congestive heart failure, pulmonary disease.

Participate

Sorry, this study is not currently accepting new participants.
Browse other research studies.

Additional information

Contact information

ASCEND@ucalgary.ca

Principal investigator:

Maitreyi Kothandaraman

Clinical trial:

Yes

REB-ID:

REB24-0781